On October 6, 2026 New Zealand’s advanced cell therapy company BioOra reported the National Party’s commitment to co‑invest $25 million to expand BioOra’s cell therapy manufacturing, research, and clinical facilities in Christchurch, New Zealand.
The commitment, set out in National’s health policy, "More medicines and earlier care", issued 6th October 2026, would support the production of CAR T-cell therapy here in New Zealand. The policy also proposes a national clinical trials target, a single front door for trials, and simpler approvals.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We welcome this commitment. Building CAR T-cell and advanced cellular therapy manufacturing in New Zealand is about sovereign capability, creating skilled jobs, and growing the biotech industry in the South Island. This is about bringing the next generation of cancer treatment closer to home for New Zealanders", said BioOra Chief Executive John Robson.
"We have engaged constructively with a range of political parties across Parliament and have been encouraged by the support we’ve seen. Sovereign biomanufacturing is a long-term national asset, and we look forward to working with government to ensure that novel cell therapies are available to New Zealanders".
Malaghan Institute of Medical Research Chief Executive Professor Kjesten Wiig said the Malaghan welcomed National’s commitment to unlocking CAR T-cell therapy in New Zealand.
"Making CAR T-cell therapy a standard of care in the public health system has been the ultimate goal of our research and development of New Zealand’s first CAR T-cell therapy, one shared with BioOra".
"Investment in the research, development and delivery of advanced therapies in New Zealand is critical for our future health and prosperity as a nation".
BioOra’s VP of Clinical and Medical Affairs, James Oughton, said the proposed clinical trial measures would also be welcomed across the sector.
"Clinical trials are one of the main ways New Zealanders get access to innovative treatments. A clearer, faster, and more consistent approvals process would make New Zealand a more attractive place to run trials, and that benefits patients, clinicians, and researchers alike".
BioOra currently manufactures a CAR T-cell therapy (atla-cel) for ENABLE-2, a Phase II trial sponsored by the Malaghan Institute of Medical Research. Our goal is to make this therapy available to New Zealand patients after the trial, subject to regulatory approval. Any therapy BioOra produces will go through New Zealand’s independent regulatory and funding processes, including Medsafe, Pharmac, and the Health Technology Evaluation Pathway (HTEP). The trial is expected to close in Q2 2027, and BioOra is committed to providing public access pathways for access to their therapy.
(Press release, BioOra, OCT 6, 2026, View Source [SID1234673211])